Segments - Rosacea Treatment Market by Drug Classes (Antibiotics, Alpha Agonists, Retinoids, Corticosteroids, Immunosuppressants, Antihypertensive Agents, and Others), Modes of Administration (Topical and Oral), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa)- Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028
The global rosacea treatment market size was valued at USD 2.5 billion in 2020 and is anticipated to expand at a CAGR of 6.7% during the forecast period, 2021-2028. The growth of the market is attributed to its consolidation nature resulting in proactive government initiatives along with the high disease occurrences.
Rosacea is a condition that causes small, red bumps on the face of the host leading to acute redness and rash to the skin. This is most commonly found in middle-aged women having fair skin and is commonly mistaken for milder skin conditions such as ache or dry skin. Key symptoms of this disease include facial redness along with visible blood vessels. This can also affect the eyes making it puffy or dry. Rosacea can be treated by medications (antibiotics, topical antiseptic, & vitamin A derivatives), self-care products (sun-block, artificial tears, and moisturizers), and medical procedures including laser therapy.
According to the World Health Organization or the WHO, along with the Centers for Disease Control and Prevention or the CDC, more than 400 million people have been affected with Rosacea on a worldwide scale. This disease is also increasing at a scale of 5% per year, now being accelerated due to the coronavirus spread. The COVID-19 pandemic has hindered the growth of the global Rosacea treatment market initially. However, upon further studies, researchers and scientists found out that the coronavirus has the viral gene of accelerating illness of the hosts. This steered to hospitals, clinics, and healthcare laboratories to focus more on the development of Rosacea treatment for the prevention and treatment of diseases and this led to its market growth in the later stages of this pandemic.
The report on the global Rosacea treatment market size includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes |
Details |
Report Title |
Rosacea Treatment Market Size - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year |
2020 |
Historic Data |
2018–2019 |
Forecast Period |
2021–2028 |
Segmentation |
Drug Classes (Antibiotics, Alpha Agonists, Retinoids,Corticosteroids,Immunosuppressants, Antihypertensive Agents, and Others) and Modes of Administration (Topical and Oral) |
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Trends, and Revenue Forecast |
Key Players Covered in the Report |
Allergan Plc; Bayer Schering AG; Bausch Health Companies Inc.; and Nestle S.A |
Antibiotics segment is projected to represent a large market share
Based on drug classes, the global Rosacea treatment market is divided into antibiotics, alpha agonists, retinoids, corticosteroids, immunosuppressants, antihypertensive agents, and others. The antibiotics segment is expected to constitute the major share in 2019. The major reason attributing to this market growth is the fact that they are the most commonly used & prescribed form of diagnosis used by physicians & doctors. Metronidazole is the most used drug to treat skin pumps and visible red vessels by simple consumption.
Meanwhile the alpha agonists segment is anticipated to grow with a significant CAGR of 7.9% during the forecast period, 2021-2028, owing to the two revenue generators which are Rhofade and Mirvaso. These products are used for the diagnosis of Rosacea associated erythema which is now increasing at an exponential scale globally.
Topical segment is estimated to register a huge market share
On the basis of modes of administration, the global Rosacea treatment market is bifurcated into topical and oral. The topical is expected to constitute the major share of 64% of the market in 2019 and is anticipated to grow with a significant CAGR during the forecast period, 2021-2028. This is attributed to the various applications that depend on the topical method, and the fact that this method is cost effective & highly efficient in the long run. Oral therapy as of now only find its application in the ocular Rosacea treatment and diagnosis.
North America is anticipated to dominate the market
On the basis of regions, the global Rosacea treatment market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market in North America is expected to constitute a major share of 49% in 2020. This regional market growth can be attributed to the growing research & development expenditure along with the rising in adoption of the latest technology. The demand of Rosacea treatment is increasing rapidly in this region due to the presence of the major market players in the Rosacea treatment market, an advantage other regions do not have. The cost of expenditure is significantly lower in North America than that of other economies. However, the market in Asia Pacific is anticipated to expand at a significant CAGR during the forecast period, 2021-2028, as they have prioritized the cost-efficiency perspective of Rosacea Treatment combined with their growing population.
Segments Covered in the Report
The global Rosacea treatment market size has been segmented in terms of
Drug Classes
Modes of Administration
Regions
Key Players
Major players competing in the global Rosacea treatment market are Allergan Plc; Bayer Schering AG; Bausch Health Companies Inc.; and Nestle S.A. These market players are involved in several business strategies such as mergers, acquisitions partnerships, collaborations, capacity expansion, and product launches to enhance their market shares. Nestle S.A have developed new products, each having their specific usages with respect to the age & the environment favorable to the drugs, namely Oracea, Soolantra, MetroGel, & Mirvaso.